US-based Pneuma Respiratory says that it has developed a digital,soft mist inhaler with an electronic droplet ejector system capable of delivering different droplet sizes. According to the company, the device has been validated by two clinical studies in COPD patients. The SMI is breath actuated and connects to a mobile app to track delivery data.
Guangxi Li of the Mayo Clinic, a member of Pneuma Respiratory’s medical advisory board, said, “The breath actuation and electronic ejection creates a lot of possibilities for practitioners. While we’re currently focused on creating improved therapeutic treatments by delivering off-patent, proven asthma and COPD medicines, we see tremendous potential to lead the successful delivery of large molecule drugs through the lungs.”
Pneuma Respiratory Director of Business Development James Bauler commented, “More than 40 million people suffer from asthma or COPD in the US. It’s well documented that patients have problems adopting the correct inhaler technique and thus receiving the expected dose of medication both with dry powder and existing metered-dose inhalers. With a proven team of technology and health care leaders, Pneuma expects to make significant gains in pulmonary drug delivery.”
Read the Pneuma Respiratory press release.